Cit­ing 'chal­leng­ing eco­nom­ic en­vi­ron­ment,' PhI­II-ready mi­cro­bio­me biotech lays off 20% of staffers

The mar­ket down­turn isn’t just sweep­ing up pub­lic biotechs.

Vedan­ta Bio­sciences, a de­vel­op­er of oral drugs de­rived from the hu­man mi­cro­bio­me, is lay­ing off about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER